A phase II trial of MRX 34 in patients with renal cell carcinoma
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 09 May 2017
At a glance
- Drugs MRX 34 (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Mirna Therapeutics
- 01 Apr 2016 New trial record
- 29 Mar 2016 According to a Mirna Therapeutics media release, this trial is expected to initiate by the end of 2016.
- 29 Mar 2016 According to a Mirna Therapeutics media release, the company plans to provide a clinical update from these studies in the second half of 2017.